(HealthDay News) — During a tense hearing before a Senate committee on Tuesday, Novo Nordisk CEO Lars Fruergaard Jørgensen faced tough questions over the company’s high prices for its blockbuster ...

The Senate investigation showed Americans pay $1,349 a month for the weight-loss drug Wegovy, which is priced at $92 in the United Kingdom.

WASHINGTON—U.S. Senator Mike Braun questioned Novo Nordisk CEO, Lars Fruergaard Jørgensen, at the Senate Health, Education, ...

Novo Nordisk said it’s open to discussions with PBMs based on their commitments that a lower semgalutide list price would not ...

Novo Nordisk has a price fix solution for uninsured patients with diabetes, but not for HSA holders or people with normal ...

Novo Nordisk CEO explains decision to discontinue the long-acting insulin Levemir. He blamed pharmacy managers and health ...

The CEO of Novo Nordisk took questions for more than two hours during a Senate Health Committee hearing focused on addressing ...

For the millions of people living with diabetes or obesity, drugs like Ozempic and Wegovy can significantly improve their ...

Sen. Bernie Sanders grilled the CEO of Novo Nordisk, the maker of Ozempic, over the price of the breakthrough diabetes and weight loss drug.

U.S. senators questioned Novo Nordisk CEO Lars Fruergaard Jørgensen about the high costs of the company's GLP-1 drugs, which include popular weight-loss drugs Wegovy and Ozempic. It comes after North ...

"All we are saying [to Novo Nordisk] is, Treat the American people the same way that you treat people all over the world.

Chairman of the Senate Committee on Health, Education, Labor, and Pensions (HELP), today led the committee in a hearing to ...